Navigation Links
Aeolus Pharmaceuticals, Inc. to Present Live, Online at RetailInvestorConferences.com on June 2nd
Date:5/26/2011

NEW YORK, May 26, 2011 /PRNewswire/ -- Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) today announced that John McManus, the company's Chief Executive Officer, will presenting at RetailInvestorConferences.com. DATE:

June 2nd, 2011TIME:

2:00 PM EDTLINK:

www.retailinvestorconferences.com > Click the red "register/ watch event now" button.This will be a live, interactive online event where investors are invited to ask the company questions in real-time both in the presentation hall as well as the company's "virtual trade booth." If attendees are not able to join the event live in real-time, an on-demand archive will be available for 90 days.

It is recommended that investors pre-register to save time and receive event updates.

About Aeolus PharmaceuticalsAeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with up to $140 million in funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to efficiently develop the compound for use in oncology.

About RetailInvestorConferences.com:RetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.


'/>"/>

SOURCE Aeolus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference
2. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
5. Pacira Pharmaceuticals, Inc. Announces Phase 3 EXPAREL™ Data Presentation at the American Society of Colon and Rectal Surgeons 2011 Annual Meeting
6. Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
7. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
8. Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
9. MHPA Center for Best Practices Receives Sponsorship from Ortho-McNeil Janssen Pharmaceuticals, Inc. to Improve Medicaid Quality, Care Coordination for Serious Mental Illness
10. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
11. Important Drug Product Notice: Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Dec 9, 2016 Research and Markets has ... report to their offering. ... The global travel vaccines market to grow at ... report covers the present scenario and the growth prospects of the ... the report considers the revenue generated from the sales of various ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences ... clinical-stage biopharmaceutical company focused on the treatment of ... data from a Phase 2b trial evaluating treatment ... donepezil, compared with donepezil plus placebo in people ... the addition of intepirdine to treatment was associated ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering.  The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy Name ... New York, NY, on December 3rd, to benefit Holy Name Medical Center's programs ... event, which raised over $1 million - the largest event in the Center's ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Cable Network (PCN) during the summer of 2016. The program was made possible ... the United States Department of Health and Human Services Administration. The broadcast, ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking attendance at ... for its 33rd Annual Issues & Research Conference, March 2-3, 2017, at ... the conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest Healthcare Properties ... by an affiliate of Seavest, has won a prestigious national healthcare real estate ... ambulatory care center (ACC) was named “Best New Development, MOBs and Other Outpatient ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, ... Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related to ... prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 with ...
Breaking Medicine News(10 mins):